Form 4: Beam Therapeutics CLO Sells Shares Under 10b5-1 Plan

Beam Therapeutics' Chief Legal Officer, Christine Bellon, sold a total of 18,629 shares of common stock on January 15, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Christine Bellon, the Chief Legal Officer of Beam Therapeutics Inc. (BEAM), reported transactions involving the sale of common stock.
• The transactions occurred on January 15, 2026.
• A total of 18,629 shares of common stock were disposed of directly.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Christine Bellon on September 16, 2025.
• The shares were sold at weighted average prices ranging from $33.6219 to $35.3988.
• Following these transactions, Christine Bellon beneficially owns 97,038 shares of Beam Therapeutics common stock.

Sentiment

Score: 5

Explanation: This Form 4 reports a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which is generally considered a neutral event as it's not typically based on new, non-public information about the company's performance.

Negatives

• An insider, the Chief Legal Officer, sold a significant number of shares (18,629) of common stock.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the insider sale, but the existence of a Rule 10b5-1 plan typically mitigates concerns that the sale is based on new negative information, as it was pre-scheduled.

Key Dates

Recommendation

The filing reports a routine insider sale executed under a pre-arranged 10b5-1 trading plan. This type of transaction is generally not indicative of a change in the company's fundamental prospects or a signal for investors to alter their positions. It's a planned liquidity event for the insider. Therefore, a 'hold' recommendation is appropriate as this specific filing does not provide new information to warrant a change in investment thesis.

Keywords

Beam Therapeutics, BEAM, insider trading, Form 4, stock sale, Christine Bellon, Chief Legal Officer, 10b5-1 plan